Synthetic Biology 2026

OECD reports that the global bioeconomy was at ~USD 4-5T in 2023 and projects that it could reach ~USD 30T by 2050. This contextualizes synthetic biology as an enabling capability for the next wave of bio-based production rather than a standalone end-market.

On capital signals, SynBioBeta’s annual investment analysis reports USD 12.2B of synthetic biology venture investment in 2024 (year-to-date) versus USD 10.7B in 2023 (global). This implies that the funding environment is selective but reopened, particularly for platforms that shorten design-build-test cycles.

Further, the US Department of Defense announced USD 1.2B in new biomanufacturing investments (reported in 2023 as “last year” announcements) for domestic production of mission-critical materials and reduced supply chain fragility. This is an important commercialization tailwind for industrial synbio and scale-up infrastructure.

Synthetic DNA – the core input for many synbio programs – has its own growth curve. The global DNA synthesis market is expected to reach USD 5.95B in 2026 and USD 24.06B by 2034 with 19.09% CAGR.

Market Context and 2026 Landscape

A USDA-supported economic impact update estimates the US biobased products industry contributed USD 489 billion to the US economy in 2021 and supported 3.94 million jobs. This highlights the demand proxy for bio-based materials, enzymes, and bioprocess outputs that synbi

On workforce comparables, there were 22 200 jobs for bioengineers and biomedical engineers in 2024 in the United States, and this is projected to grow by 5% from 2024 to 2034. This provides a conservative anchor for talent availability and hiring pressure in adjacent roles that feed synthetic biology programs.

To frame competitive geography in applied biotech innovation, MERICS reports that China’s biotech PCT patents rose from 119 (2010) to 1918 (2023). At the same time, EU27 registered 1369 and the US 3721 biotech PCT patents in 2023. This signals a widening set of regions that can originate protectable biotech inventions and later compete on a manufacturing scale.

The StartUs Insights Discovery Platform has recorded approximately 3600 companies with 430+ startups operating across the synthetic biology value chain.

At the city level, London, Cambridge, San Francisco, New York City, and Boston serve as the primary centers for research, commercialization, and venture activity.

 

 

Startup Reality Check: 430+ Young Companies as Scale-Up Financing Moves

Bioinsumos Brasil – Phytopathogen-resistant Bacteria

Brazilian startup Bioinsumos Brasil develops BioElicit, a recombinant bio-input product for enhancing soybean resistance to phytopathogens.

It combines selected Bacillus strains with recombinant elicitor proteins produced through synthetic biology. This activates the plant’s natural defense mechanisms and enables it to respond more effectively to future infections.

The formulation promotes plant growth, improves nutrient availability, and supports soil fertility while reducing reliance on chemical pesticides.

The startup also leverages its AgroFast platform to optimize bacterial strains, culture media, formulation, and scalable production to achieve high colony-forming unit concentration and consistent performance.

Raina Biosciences – AI-designed mRNA Sequences

US-based startup Raina Biosciences makes GEMORNA, a generative AI platform for designing optimized mRNA therapeutics.

It uses a proprietary generative AI engine to explore a multi-dimensional sequence design space and optimize coding and regulatory elements.

The platform then produces mRNA candidates with improved expression, stability, and durability, followed by high-throughput gene synthesis and experimental validation in a closed-loop workflow.

The platform enables zero-shot sequence generation and rapid preclinical optimization across multiple applications. The startup applies these capabilities to advance mRNA vaccines, cell therapies, and other modalities involving synthetic RNA with experimentally validated performance gains.

Vesiculate – Synthetic Vesicle Nanoparticle Platform

Australian startup Vesiculate makes Syncles, a synthetic vesicle nanoparticle platform for advanced analytical and reagent applications.

It forms hollow, membrane-bound nanoparticles with a solvent-filled core and tunable surface properties. These are created using fully synthetic, non-lipid bilayer membranes that provide precise control over structure and chemistry.

In addition, the platform delivers chemical and physical stability. Also, it offers broad compatibility across buffers, pH ranges, and organic solvents, and supports monodisperse, fluorescent, and reactive vesicle formats for single-particle analysis and instrument standardization.

Skape Bio – AI-driven Drug Discovery Platform

Danish startup Skape Bio makes an AI-driven drug discovery platform for designing functional biologics that modulate G protein-coupled receptors (GPCR).

It unites generative protein design with native receptor biology and scalable in-cell high-throughput screening to create de novo miniproteins. These act as GPCR agonists and antagonists without requiring receptor solubilization or mutation.

The platform integrates atomic-level structural validation and screening in human cells to deliver precise receptor modulation across diverse GPCR families. As a result, it enables access to GPCR targets that remain difficult to address with traditional small molecules or antibodies.

Blue Bite Biotech – Enzymatic Plastic Recycling

Swiss startup Blue Bite Biotech develops an enzymatic recycling platform for depolymerizing PET into high-purity base monomers.

It applies a proprietary mixture of enzymes that selectively break PET polymer chains under mild operating conditions. This is followed by controlled separation and purification processes that yield purified terephthalic acid (PTA) and monoethylene glycol (MEG) suitable for repolymerization.

The startup integrates bioinformatics-driven enzyme discovery, synthetic biology-based protein engineering, and process optimization to improve activity, stability, selectivity, and scalability. This reduces energy use, limits side reactions, and delivers consistent pharmaceutical-grade monomer purity.

Tools That Change the Cost Curve

More than 29 300 applicants operating in the synthetic biology sector filed approximately 93 900 patents. However, the yearly patent growth rate of 0.47% suggests that while the volume of intellectual property is high, new patent filings are growing at a measured pace.

Discover the emerging trends in the synthetic biology market along with their firmographic details:

Genetic Engineering

Over 3100 companies operate in this segment, while employing approximately 294 800 people worldwide. Over the past year, the segment added 125+ new employees.

The annual growth rate of 5.04% highlights advances in gene editing tools, synthetic DNA design, and cellular engineering that are driving applications across healthcare, industrial biotechnology, and agriculture.

Next Generation Sequencing (NGS)

Our database has recorded over 1700 NGS companies operating in this segment, with a combined workforce of approximately 178 400 employees. In the last year, the segment recorded 85+ new hires.

The annual growth rate of 4.55% indicates stable, moderate expansion. NGS highlights data-driven biology by enabling high-throughput genomic analysis, design-build-test cycles, and precision engineering of biological systems.

Alternative Protein

There are about 4200 companies active in the alternative protein area, employing around 27 200 people. Notably, the segment added 205+ new employees in the last year.

With an annual growth rate of 8.77%, alternative protein advances in cellular agriculture, precision fermentation, and plant-based protein engineering, as well as sustainable food systems.

Capital Map: $12.2B SynBio VC Plus a $1B DoD Push

At the federal strategy layer, a White House fact sheet states the DoD will invest USD 1 billion over five years in bioindustrial domestic manufacturing infrastructure. This is a long-horizon signal that derisks capacity build-out for fermentation, downstream processing, and bio-based chemicals relying on engineered organisms.

Europe’s programmatic funding is similarly explicit. CBE JU describes itself as a EUR 2 billion partnership (EU + Bio-based Industries Consortium), and it announced EUR 170.7 million for calls accelerating bio-based solutions in 2026.

The average investment value stands at USD 22.4 million per funding round, which indicates sustained capital deployment across early-stage research ventures as well as later-stage companies advancing toward commercialization.

The venture investments in this industry reached USD 12.2 billion year-to-date, increasing from USD 10.7 billion in 2023.

In the fourth quarter of 2024, synthetic biology startups raised USD 4.3 billion in funding, representing a $2.6 billion increase (59.2%) compared with the USD 1.8 billion raised in the previous quarter.

Funding levels were also significantly higher than in the same quarter a year earlier, when startups raised USD 1.7 billion, reflecting a USD 2.6 billion year-over-year increase.

On a year-to-date basis, synthetic biology startups have secured USD 12.2 billion, up from USD 10.7 billion at the same point last year, an increase of USD 1.5 billion.

 

Credit: SynBioBeta

Research Method and Data

This Synthetic Biology 2026 outlook is built using the StartUs Insights Discovery Platform, which continuously maps 9M+ companies, 25K+ technologies and trends, and 190M+ patents, news articles, and market reports. The analysis benchmarks a tracked universe of 3600+ companies and 430+ startups, connects their activity to 93 900+ patent signals, and cross-references capital formation across ~5,600 funding rounds to isolate where commercialization is compounding versus where it is stalling.

The lens centers on the operational chokepoints that decide whether engineered biology becomes repeatable industrial output. The report therefore treats synthetic biology less as a set of lab techniques and more as a production system – tracking how platform players convert discovery into throughput, how manufacturers finance scale, and more.